2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1722

What Is the Clinical Utility of MR Imaging in the Management of Nr-Axspa Patients?
Abstract Number: 1292

What Is the Effect of TNF Inhibitors on Employment Status in Rheumatoid Arthritis Patients and What Are the Predictors of Progression to Unemployment?
Abstract Number: 1546

What Is the Impact of Smoking on the Risk of Rheumatoid Arthritis Progression: A Systematic Review of the Risk Factor Paradox
Abstract Number: 2879

What Is the Location of Dactylitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Abstract Number: 2877

What Is the Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond to Anti-TNF Treatment?
Abstract Number: 1001

What Is the Most Cost-Effective Physical Therapy Strategy to Treat Knee Osteoarthritis?
Abstract Number: 2783

What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Abstract Number: 1330

What Is the Reliability of Recognizing Structural MRI Lesions of Sacroiliac Joints in Patients with Recent Inflammatory Back Pain in Clinical Practice?
Abstract Number: 2744

What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Abstract Number: 2603

What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?
Abstract Number: 2477

What Older Adults with Restricting Back Pain Worry about: Deteriorating Function, Reliance on Others, Distrust of Medications
Abstract Number: 676

What Proportion of Patients with Psa Fail to Achieve MDA Based on Patient Reported Outcomes? an Analysis from a Prospective, Observational Registry
Abstract Number: 2293

What Types of Exercises Can Fibromyalgia Patients Perform?
Abstract Number: 160

When Compared with a Computerized System Both Experienced and in-Training Sonographers Have Difficulties to Select the Best Doppler Image from a Cine-Loop
Abstract Number: 914

When Fibromyalgia Criteria Misclassify

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].